Zacks Investment Research upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a hold rating to a buy rating in a research note published on Friday morning. The firm currently has $13.00 target price on the stock.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other equities analysts have also recently weighed in on the stock. HC Wainwright reiterated a hold rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. Cann reiterated a buy rating and issued a $26.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. BidaskClub cut shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, July 26th. Cowen reiterated a buy rating on shares of Syros Pharmaceuticals in a research note on Tuesday, July 17th. Finally, ValuEngine upgraded shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, July 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Syros Pharmaceuticals has a consensus rating of Buy and a consensus target price of $21.00.

Shares of NASDAQ:SYRS opened at $12.06 on Friday. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $23.61. The company has a market capitalization of $411.25 million, a PE ratio of -5.62 and a beta of -2.44.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.07. The business had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.33 million. research analysts expect that Syros Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in Syros Pharmaceuticals by 13.9% in the 1st quarter. JPMorgan Chase & Co. now owns 374,513 shares of the company’s stock worth $4,861,000 after acquiring an additional 45,715 shares in the last quarter. Northern Trust Corp increased its holdings in Syros Pharmaceuticals by 35.0% in the 1st quarter. Northern Trust Corp now owns 181,090 shares of the company’s stock worth $2,351,000 after acquiring an additional 46,927 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in Syros Pharmaceuticals in the 4th quarter worth approximately $105,000. BlackRock Inc. increased its holdings in Syros Pharmaceuticals by 61.7% in the 1st quarter. BlackRock Inc. now owns 929,537 shares of the company’s stock worth $12,066,000 after acquiring an additional 354,591 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in Syros Pharmaceuticals by 159.3% in the 1st quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock worth $21,446,000 after acquiring an additional 1,015,008 shares in the last quarter. 57.45% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Read More: Diversification For Individual Investors

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.